What warning did the FDA remove from menopause medications?

The FDA removed a 2003 black-box warning concerning risks of cardiovascular disease, breast cancer, and dementia associated with estrogen-related medications.

Why are experts criticizing the FDA's decision on hormone therapy?

Experts argue the FDA panel made baseless claims about unproven health benefits and conflated distinct issues related to local and systemic estrogen.

What are the scientific concerns regarding hormone therapy for menopause?

While effective for symptoms, there is limited evidence that hormone therapy benefits the wider population of menopausal women beyond symptom relief, especially for preventing diseases like dementia.

Home / Health / Experts Criticize FDA for Baseless Hormone Therapy Claims

Experts Criticize FDA for Baseless Hormone Therapy Claims

24 Nov

•

Summary

FDA panel removed black-box warnings for menopause drugs, bypassing typical process.
Experts claim the FDA panel conflated issues and made unsupported health benefit claims.
The decision sets a concerning precedent for future drug regulatory decisions.

Experts Criticize FDA for Baseless Hormone Therapy Claims

The U.S. Food and Drug Administration (FDA) has announced the removal of broad black-box warnings from estrogen-related medications used for menopause, a decision that has sparked significant controversy among medical professionals. Experts contend that the FDA panel bypassed standard procedures and overstated the scientific evidence regarding the drugs' purported health benefits, including prevention of heart disease and dementia.

Physicians and researchers argue that the panel conflated issues concerning local vaginal estrogen products with those of systemic estrogen, which has more complex considerations. While hormone therapy can alleviate menopausal symptoms like hot flashes, claims of its widespread efficacy in preventing serious conditions such as Alzheimer's disease and heart disease lack robust scientific backing for the general menopausal population. Experts express concern over the "data-free" decision and its confusing implications for women seeking accurate health information.